Flatlander schreef op 24 maart 2020 14:18:
DWZ
How did you get a $300 million Convertible? Everything I read indicated 150 million.
www.pm360online.com/biocartis-group-n...Also, by 2024 the bondholders can convert the bonds for common stock shares so the entire offering amount is not made in a cash payout. I realize that this assumes that the share price increases by 2024 such that conversion occurs. I'm confident this happens as more assays gain approval for diagnostic use in the next year or two.
Finally, if we can take Verrelst at his word the cash burn rate should decrease in 2021. I realize that CV is thrown a lot of sand into the gears in terms of timing. However, you are not considering that Aisian economies recovering from the recession (and they are done with the worst of it already) will want to stimulate heavily. Approval of Idylla registration applications for an Assay product that is well documented and tested will be a no brainer.
FL